SCHEMBL31023799

SCHEMBL31023799

COc1ccc(N(c2ccc3c(c2)OCO3)C2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMP1 P13497 1/20 0.54
MAPT P10636 3/20 0.53
GPR119 Q8TDV5 1/20 0.52
TP53 P04637 2/20 0.51
THRB P10828 2/20 0.51
ALDH1A1 P00352 1/20 0.50
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
STS P08842 2/20 0.46
EPHX2 P34913 1/20 0.46
HTT P42858 1/20 0.46
SCD5 Q86SK9 1/20 0.46
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
MMP13 P45452 1/20 0.43
CTSD P07339 1/20 0.43
CTSE P14091 1/20 0.43
BACE1 P56817 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023747 0.93 SCD5 (0.51) BMP1MAPTGPR119TP53MEN1
SCHEMBL31023933 0.89 MEN1 (0.55) BMP1MAPTTP53MEN1KMT2A
SCHEMBL31023722 0.89 MGLL (0.49) BMP1MAPTGPR119TP53MEN1
SCHEMBL31023784 0.87 SMN1; SMN2 (0.48) BMP1MAPTALDH1A1MEN1KMT2A
SCHEMBL31023876 0.83 CYP3A4 (0.53) MAPTGPR119TP53SCD5
SCHEMBL31023770 0.82 MEN1 (0.61) GPR119ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL31023843 0.75 ALDH1A1 (0.40) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL25389387 0.75 MEN1 (0.68) GPR119MEN1KMT2AMMP13
SCHEMBL16744482 0.75 MGLL (0.55) BMP1MAPTGPR119TP53THRB
SCHEMBL5450791 0.75 GPR119 (0.60) GPR119ALDH1A1MEN1KMT2ASTS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 US disclosed
WO-2024168426-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL BMP1 4058/4885MAPT 88/4885GPR119 453/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL BMP1 4058/4885MAPT 88/4885GPR119 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.